The Global Health Body Raises Alert Over Acute Scarcity of Obesity Injections
Less than a tenth of patients eligible to benefit from obesity jabs including Wegovy have access to them, states the World Health Organization as it publishes its first guidance on the therapies.
Considering over a billion individuals worldwide currently classified as obese, it is calling for more widespread and fairer availability to GLP-1 medication.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"The new guidelines affirms that excess weight is a chronic disease that can be addressed with thorough and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are key obstacles to widespread availability to the jabs that can aid individuals in losing substantial weight, explains the body.
Skinny Jab Supply Crisis
Even in the present most favorable case, the supply of these medications might only reach approximately 100 million people – under 10% of the global need, per the WHO.
The advice encourages countries and companies to expand access, through measures including licensing agreements.
Exclusive production rights on semaglutide – the primary ingredient of the drug Wegovy – is set to lapse in several countries in 2026.
How Obesity Injections Function
The injections imitate a body's own hormone to delay gastric emptying, suppress the appetite and boost the sense of being full so people consume fewer calories.
Individuals commonly begin shedding pounds within a few weeks of commencing the regular doses.
Evidence points to users may regain a significant portion after a year of halting the treatment, as their normal hunger come back.
Being overweight or obese elevates your likelihood for contracting diseases, like type 2 diabetes, heart disease, stroke, and specific malignancies.
Excess weight affects people in all nations and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.
